Compare FLWS & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLWS | FENC |
|---|---|---|
| Founded | 1976 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.5M | 230.8M |
| IPO Year | 1999 | 2010 |
| Metric | FLWS | FENC |
|---|---|---|
| Price | $4.55 | $9.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | ★ 787.9K | 336.6K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $1,151,921,000.00 | $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $1,000.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.89 | $5.65 |
| 52 Week High | $8.44 | $10.45 |
| Indicator | FLWS | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 72.82 |
| Support Level | $3.07 | $7.45 |
| Resistance Level | $5.08 | $9.92 |
| Average True Range (ATR) | 0.32 | 0.65 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 75.23 | 82.70 |
1-800-Flowers.com Inc is a provider of gifts designed to help customers express, connect, and celebrate. The company's e-commerce business platform features all brands, including 1-800-Flowers.com, 1-800-Baskets.com, Cheryl's Cookies, Harry and David, PersonalizationMall.com, Shari's Berries, FruitBouquets.com, Moose Munch, The Popcorn Factory, Wolferman's Bakery, Stock Yards, and Simply Chocolate. The company's business segments are; Consumer Floral and Gifts, BloomNet, and Gourmet Foods & Gift Baskets. The maximum revenue for the company is generated from its Gourmet Foods & Gift Baskets segment.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.